Amy Rappaport

4.3k total citations · 1 hit paper
19 papers, 2.8k citations indexed

About

Amy Rappaport is a scholar working on Molecular Biology, Hematology and Ecology, Evolution, Behavior and Systematics. According to data from OpenAlex, Amy Rappaport has authored 19 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Hematology and 2 papers in Ecology, Evolution, Behavior and Systematics. Recurrent topics in Amy Rappaport's work include Acute Myeloid Leukemia Research (8 papers), Protein Degradation and Inhibitors (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Amy Rappaport is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Protein Degradation and Inhibitors (7 papers) and Histone Deacetylase Inhibitors Research (5 papers). Amy Rappaport collaborates with scholars based in United States, Austria and Australia. Amy Rappaport's co-authors include Johannes Zuber, Scott W. Lowe, Scott C. Kogan, Christopher R. Vakoc, Eric Wang, Junwei Shi, Meredith J. Taylor, James E. Bradner, Christopher Johns and Peter Valent and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Amy Rappaport

18 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

2011 1.4k citations Johannes Zuber, Junwei Shi et al. Nature profile →

Peers

Countries citing papers authored by Amy Rappaport

Since Specialization

Citations

This map shows the geographic impact of Amy Rappaport's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Rappaport with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Rappaport more than expected).

Fields of papers citing papers by Amy Rappaport

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Rappaport. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Rappaport. The network helps show where Amy Rappaport may publish in the future.

Co-authorship network of co-authors of Amy Rappaport

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Rappaport. A scholar is included among the top collaborators of Amy Rappaport based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Rappaport. Amy Rappaport is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Differential shaping of T cell responses elicited by heterologous ChAd68/self-amplifying mRNA SIV vaccine in macaques in combination with αCTLA4, αPD-1, or FLT3R agonist 2025 ·The Journal of Immunology ·Amy Rappaport, Elena Bekerman, (unknown), (unknown), Brian Carr, Cesar A. Corzo, (unknown), (unknown), Ciaran D. Scallan, Romas Geleziunas, Devi SenGupta, Karin Jooss	1
2	Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection 2022 ·Nature Communications ·Amy Rappaport, (unknown), Ciaran D. Scallan, Leonid Gitlin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Annie Shen, (unknown), Anne van Abbema, (unknown), Karin Jooss	33
3	Abstract 4159: Lower doses of self-amplifying mRNA drive superior neoantigen-specific CD8 T cell responses in cancer patients versus high doses 2022 ·Cancer Research ·Christine D. Palmer, Amy Rappaport, Meghan G. Hart, (unknown), Sonia Kounlavouth, (unknown), (unknown), (unknown), Annie Shen, (unknown), (unknown), Ciaran D. Scallan, Sue‐Jean Hong, Leonid Gitlin, Alexander I. Spira, Chrisann Kyi, Daniel V.T. Catenacci, Raphaël F. Rousseau, Andrew L. Ferguson, Karin Jooss	1
4	How do I work with fertility loss as a pregnant therapist? A case study and discussion about pregnancy self-disclosure in the oncology setting 2021 ·Journal of Psychosocial Oncology ·Melanie McDonald, Amy Rappaport, Alan Bates	0
5	Direct and indirect targeting of MYC to treat acute myeloid leukemia 2015 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), Alexandra Corella, Johannes Zuber, Amy Rappaport, (unknown), Scott W. Lowe, Andrei Goga, Scott C. Kogan	33
6	Genetically Engineered Knock-In and Conditional Knock-In Mouse Models of Cancer 2014 ·Cold Spring Harbor Protocols ·Amy Rappaport, Leisa Johnson	5
7	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia 2014 ·Cancer Cell ·Chong Chen, Yu Liu, Amy Rappaport, Thomas Kitzing, Nikolaus Schultz, Zhen Zhao, Aditya Shroff, Ross A. Dickins, Christopher R. Vakoc, James E. Bradner, Wendy Stock, Michelle M. LeBeau, Kevin Shannon, Scott C. Kogan, Johannes Zuber, Scott W. Lowe	230
8	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors 2014 ·Blood ·Michael Bots, Inge Verbrugge, Benjamin P. Martin, Jessica M. Salmon, Margherita Ghisi, Adele Baker, Kym L. Stanley, Jake Shortt, Gert J. Ossenkoppele, Johannes Zuber, Amy Rappaport, Peter Atadja, Scott W. Lowe, Ricky W. Johnstone	99
9	Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia 2012 ·Genes & Development ·Stefan Glaser, Erinna F. Lee, (unknown), Philippe Bouillet, Andrew H. Wei, W. Douglas Fairlie, David J. Izon, Johannes Zuber, Amy Rappaport, Marco J. Herold, Warren S. Alexander, Scott W. Lowe, Lorraine Robb, Andreas Strasser	317
10	The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia 2012 ·Oncogene ·Junwei Shi, Eric Wang, Johannes Zuber, Amy Rappaport, Meredith J. Taylor, Christopher Johns, S. W. Lowe, Christopher R. Vakoc	95
11	A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions 2012 ·Proceedings of the National Academy of Sciences ·Wen Xue, Thomas Kitzing, Stéphanie Roessler, Johannes Zuber, Alexander Krasnitz, Nikolaus Schultz, Kate Revill, Susann Weissmueller, Amy Rappaport, Janelle Simon, Jack Zhang, Weijun Luo, James Hicks, Lars Zender, Xin Wei Wang, Scott Powers, Michael Wigler, Scott W. Lowe	107
12	An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model 2012 ·Blood ·(unknown), Lara S. Collier, Aaron L. Sarver, (unknown), Sanne Lugthart, Miechaleen D. Diers, Johannes Zuber, Amy Rappaport, (unknown), Kevin A.T. Silverstein, Danhua Fan, (unknown), Linda Wolff, John H. Kersey, Ruud Delwel, Scott W. Lowe, Maeve O’Sullivan, Scott C. Kogan, David J. Adams, David A. Largaespada	17
13	An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance 2011 ·Genes & Development ·Johannes Zuber, Amy Rappaport, Weijun Luo, Eric Wang, Chong Chen, Angelina V. Vaseva, Junwei Shi, Susann Weissmueller, (unknown), Meredith J. Taylor, (unknown), Thomas G. Graeber, Scott C. Kogan, Christopher R. Vakoc, Scott W. Lowe	207
14	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia breakdown → 2011 ·Nature ·Johannes Zuber, Junwei Shi, Eric Wang, Amy Rappaport, Harald Herrmann, Edward Allan R. Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich, Meredith J. Taylor, Christopher Johns, Agustin Chicas, James C. Mulloy, Scott C. Kogan, Patrick A. Brown, Peter Valent, James E. Bradner, Scott W. Lowe, Christopher R. Vakoc	1438
15	Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias 2011 ·Blood ·Nadine Hein, Megan J. Bywater, Kim Stanley, Inge Verbrugge, Carleen Cullinane, Adele Baker, (unknown), Amy Rappaport, Denis Drygin, Nanni Huser, Josh Bliesath, David M. Ryckman, William G. Rice, Scott W. Lowe, Ricky W. Johnstone, Richard B. Pearson, Grant A. McArthur, Ross D. Hannan	4
16	Small-Molecule Inhibition of BRD4 Is a Novel Promising Approach to Therapeutically Target Leukemia Stem Cells in AML, 2011 ·Blood ·Harald Herrmann, Katharina Blatt, Junwei Shi, Amy Rappaport, Karoline V. Gleixner, Sabine Cerny‐Reiterer, Barbara Peter, Eric Wang, Wolfgang R. Sperr, James E. Bradner, Scott W. Lowe, Christopher R. Vakoc, Johannes Zuber, Peter Valent	2
17	Mouse models of human AML accurately predict chemotherapy response 2009 ·Genes & Development ·Johannes Zuber, Ina Radtke, Timothy S. Pardee, Zhen Zhao, Amy Rappaport, Weijun Luo, Mila E. McCurrach, (unknown), M. Eileen Dolan, Scott C. Kogan, James R. Downing, Scott W. Lowe	201
18	Geographic Variation in Contact Calls of Feral North American Populations of the Monk Parakeet 2007 ·Ornithological Applications ·(unknown), Amy Rappaport, Jack W. Bradbury	10
19	GEOGRAPHIC VARIATION IN CONTACT CALLS OF FERAL NORTH AMERICAN POPULATIONS OF THE MONK PARAKEET 2007 ·Ornithological Applications ·(unknown), Amy Rappaport, Jack W. Bradbury	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact